Associated Papers
Molecular Features and Actionable Gene Targets of Testicular Germ Cell Tumors in a Real-World Setting.
Morales-Grimany R et al.
International Journal of Molecular Sciences, 2025
Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.
Pejaver V et al.
American Journal of Human Genetics, 2022
36413997 (PubMed )
Supplement: mmc2.xlsx › mmc2
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.
Tabata J et al.
Cancer Research, 2022
36166639 (PubMed )
Supplement: can-22-0834_supplementary_table_s1_suppst1.xlsx › Supplementary_Table_S1
An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L et al.
Scientific Reports, 2022
35978072 (PubMed )
Supplement: 41598_2022_17791_MOESM3_ESM.xlsx › table
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy.
Neron M et al.
Journal of Personalized Medicine, 2022
35629078 (PubMed )
Supplement: jpm-12-00655-s001.zip › Supplementary_tables__MC20220419.xlsx › Table_S4
Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B et al.
Aging, 2020
32091409 (PubMed )
Supplement: aging-12-102783-s001..xlsx › Sheet1
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
32976510 (PubMed )
Supplement: pone.0237802.s009.zip › Table_9_Accuracy_Short_Variant_Line_Data.xlsx › sheet_1
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C et al.
Jama Oncology, 2019
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
25425582 (PubMed )
Supplement: supp_ERC-14-0491_Supplementary_table_2.xlsx › Sheet1
Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.
Crockett DK et al.
Genome Medicine, 2012
22640420 (PubMed )
Supplement: gm347-S2.DOC
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
de Groot JW et al.
Endocrine Reviews, 2006
Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.
Ahmed SA et al.
The Journal of Molecular Diagnostics : Jmd, 2005
Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma.
Siegelman M et al.
Clinical Chemistry, 1997
Select a paper to view details